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http://dx.doiabstractBACKGROUND: Tuberous sclerosis complex is an autosomal dominant disorder predisposing to the development of
benign lesions in different body organs, mainly in the brain, kidney, liver, skin, heart, and lung. Subependymal giant
cell astrocytomas are characteristic brain tumors that occur in 10% to 20% of tuberous sclerosis complex patients and
are almost exclusively related to tuberous sclerosis complex. Subependymal giant cell astrocytomas usually grow
slowly, but their progression ultimately leads to the occlusion of the foramen of Monro, with subsequent increased
intracranial pressure and hydrocephalus, thus necessitating intervention. During recent years, secondary to
improved understanding in the biological and genetic basis of tuberous sclerosis complex, mammalian target of
rapamycin inhibitors have been shown to be effective in the treatment of subependymal giant cell astrocytomas,
becoming an alternative therapeutic option to surgery. METHODS: In June 2012, an International Tuberous Sclerosis
Complex Consensus Conference was convened, during which an expert panel revised the diagnostic criteria and
considered treatment options for subependymal giant cell astrocytomas. This article summarizes the subpanel’s
recommendations regarding subependymal giant cell astrocytomas. CONCLUSIONS: Mammalian target of rapamycin
inhibitors have been shown to be an effective treatment of various aspects of tuberous sclerosis complex, including
subependymal giant cell astrocytomas. Bothmammalian target of rapamycin inhibitors and surgery have a role in the
treatment of subependymal giant cell astrocytomas. Various subependymal giant cell astrocytomaerelated condi-
tions favor a certain treatment.
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Tuberous sclerosis complex (TSC) is an autosomal
dominant disorder with high penetrance and variability and
characterized by the formation of benign lesions in multiple
organ systems, mainly in the brain, kidney, liver, skin, heart,
and lung.1-3 Incidence of TSC is estimated to be 1:6000.4
The clinical manifestations result from mutations in
either of two tumor suppressor genes: TSC1 (located on-NC-ND license. 
J. Roth et al. / Pediatric Neurology 49 (2013) 439e4444409q34) or TSC2 (located on 16p13).5 Protein products of the
TSC1 and TSC2 genes, hamartin and tuberin, respectively,
form a heterodimer that suppresses the mammalian target
of rapamycin (mTOR), a major cell growth and proliferation
controller. In TSC, increased mTOR activation leads to
disorganized cellular overgrowth, abnormal differentiation,
increased protein translation, and the formation of tumors.
Characteristic TSC brain lesions include cortical tubers,
subependymal nodules (SENs), and subependymal giant
cell astrocytomas (SEGAs). The latter occur in 10% to 20% of
TSC patients and are a major cause of TSC-related morbidity
and mortality during the pediatric age.6
In June 2012, an International Tuberous Sclerosis Com-
plex Consensus Conference convened to revise the diag-
nostic criteria for TSC along with the guidelines for its
management.7,8 This paper summarizes the work of a sub-
group of conference participants who reviewed the diag-
nosis and management of SEGAs.
Deﬁnitions and terms
Tubers are pathognomonic for TSC and present in 80% to
100% of patients. They arise supratentorially and, in about
25% to 33%, also infratentorially.9,10 Tubers are a collection
of abnormal neurons and glia usually located in the cortex,
stable throughout life, and thought to be possibly associated
with seizure and autistic spectrum disorder.
SENs are usually small asymptomatic, intraventricular
calciﬁed protrusions, appearing in more than 90% of pa-
tients. They are located in the lateral ventricles and, as
recently shown in a large cohort of patients, can be located
adjacent to the caudate nucleus (in the lateral ventricle,
atrium, and temporal horns).11 SEGAs are benign tumors
(World Health Organization I) of glioneuronal origin,
distinct from astrocytomas. Several authors have suggested
using the term “subependymal giant cell tumor”; however,
most authors still use the term SEGA.
SEGAs typically arise at the caudothalamic groove adja-
cent to the foramen of Monro. In the past, many of these
tumors were diagnosed late, with patients presenting with
symptoms of elevated intracranial pressure from obstruc-
tive hydrocephalus. In the current era of magnetic reso-
nance imaging neuroimaging, many of these tumors are
now diagnosed at an early stage as part of the screening
process of TSC patients. These slow-growing tumors rarely
arise de novo (i.e., a new lesion that was not present on
prior scans) after the age of 20-25; however, a known SEGA
may grow at an older age.
Exceptions to the typical intraventricular location of
SEGAs may occur, and extraventricular lesions have been
described.12 SEGAs may arise bilaterally or at several
different locations; invasive lesions invading the fornix,
hypothalamus, basal ganglia, and genu of the internal
capsule have been reported.
The literature is conﬂicting regarding the potential of
SENs to transform into SEGAs and does not clearly delineate
the radiological differences between these two lesions.
Some authors believe that SEGAs arise from SENs3; how-
ever, this is controversial.11 SENs and SEGAs have similar
histopathological features,13 although SENs are rarely
examined because they are virtually never resected. The
main differences between SENs and SEGAs are size (withcutoff size ranging between 5 and 10 mm) and location:
SEGAs are typically at the caudothalamic groove as opposed
to SENs that are located in the ependymal lining of the
lateral ventricles along the caudate nucleus.11 Usually SENs
are calciﬁed and nonenhancing lesions, whereas SEGAs
show avid enhancement after contrast; however, the
radiologic appearance of both pathologies may overlap.
Regardless, the most important difference between these
two TSC brain lesions is evidence of serial growth: SEGAs
will grow, whereas SENs remain stable in size.
Diagnostic criteria
Before the 2012 consensus conference, the diagnostic
criteria developed for TSC during the 1998 consensus
meeting were still in use.14
At the 2012 Washington Consensus Conference, it was
decided by the invited expert panel to document the diag-
nostic criteria related to TSC brain lesions in the following
manner:7
1. The presence of tubers (and other types of cortical
dysplasia, such as cortical migration lines), SENs, or
SEGAs will each individually be deﬁned as major criteria
(twomajor criteriawill sufﬁce for the diagnosis of TSC as
previously deﬁned in 1998).
2. For diagnostic purposes, the deﬁnition of SEGAs will
include a lesion at the caudothalamic groove with either
a size of more than 1 cm in any direction or a sub-
ependymal lesion at any location that has shown serial
growth on consecutive imaging regardless of size. Most
SEGAs will show avid enhancement after contrast
administration; however, a growing subependymal
lesion even in the absence of enhancement should be
considered a SEGA.Screening protocols
Current evidence suggests, even though literature
regarding the natural history of SEGAs is sparse, that new
SEGAs very rarely arise after 20-25 years of age.6
Hence brain imaging, preferably magnetic resonance
imaging with and without contrast, should be performed
every 1 to 3 years until the age of 25 years. Because of a lack
of knowledge of SEGA growth behavior beyond 25 years of
age, follow-up magnetic resonance imaging may not be
needed every 3 years but intervals may be prolonged in the
presence of a stable lesion and a stable patient.
Screening and follow-up scans frequency should be
tailored according to various clinical factors. New onset of
symptoms such as headaches, visual complaints, nausea or
vomiting, or increase in seizure activity should trigger an
earlier scan. Similarly, a growing SEGA should prompt a
more frequent clinical and radiological follow-up. Parents
and patients should be educated regarding relevant symp-
toms that should prompt referral to medical evaluation.
Treatment of SEGA
Treatment of SEGAs has been solely surgical because of a
lack of responsiveness to other strategies such as
FIGURE 1.
Two girls ([A], 9 and [B], 12 years old) with acute headaches and vomiting. On examination, both had papilledema. Brain magnetic resonance imaging shows
ventricular subependymal giant cell astrocytomas with secondary hydrocephalus. Surgical resection is recommended in this situation.
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associated with an increased risk of secondary malig-
nancies.15 Many retrospective series have focused on sur-
gical outcome, some of which include a heterogeneous
group of patients with very different tumor anatomy and
size as well as major differences in the number of patients
treated; hence, there are different conclusions regarding
risk of mortality, morbidities, and outcomes.16-22
Generally, it is agreed that small tumors are usually less
invasive, and that resecting noninvasive small tumors,
diagnosed while still asymptomatic, is associated with
excellent clinical outcomes, with low morbidity and mor-
tality. However, when diagnosed at a later stage, the tumor
more often affects and invades neighboring structures such
as the fornix, hypothalamus, basal ganglia, and genu of
internal capsule, and resection is associated with higher
surgical morbidity and mortality.20
Recent prospective trials documented successful SEGA
shrinkage with mTOR inhibitors (mTORi).23-26 In two large
prospective studies, the mTOR inhibitor everolimus signif-
icantly decreased the volume (>50%) of SEGAs in 35% to 42%
at 6 months of treatment.23,25 Long-term efﬁcacy and safety
has been demonstrated for up to 3.5 years in prospective
studies with everolimus. Patients from the initial report of
rapamycin for SEGAs have been receiving this agent for in
excess of 10 years with acceptable adverse events. It may be
possible to reduce the dose of mTORi after an initial
response with preservation of tumor volume reduction.24
Despite these encouraging results, for unknown reasons,
the response to mTORi is variable. SEGA growth during
mTORi therapy is extremely uncommon, and most of the
individuals who exhibit such growth have remained
asymptomatic.25,27 Also, although usually insigniﬁcant,
mTORi use is associated with side effects, most common of
which are stomatitis and upper respiratory tract infections.
Additionally, it has been shown that cessation of treatment
may result in tumor regrowth.28
Several recent review articles have presented the relative
advantages and disadvantages of surgical versus pharmaco-
logical treatment.29-31 Current practice still is dependent on
theexperienceof the individualphysician.Despite thegrowing
evidence on mTORi-induced SEGA shrinkage, many centers
still strictly advocate surgical treatment,whereas others prefermedical therapy. Institutional expertise is certainly essential in
respect to treatment choices. The risk of surgical morbidity
must be weighed against a potential lifelong medical therapy
with potential long-term risks yet to be determined. Incom-
pletely resected SEGAwill growagain; therefore, the following
aspects may aid in the decision making.
Based on extensive discussions by the expert panel, we
recommend that treatment decisions should be balanced
and should be based on multiple factors that are unique to
the individual TSC patient, including his or her clinical
condition, anatomic considerations speciﬁc to the SEGA,
surgeon experience, experience of the center with using
mTORi, prior history of SEGA resection, other TSC related
comorbidities, and patient/parental preference.Clinical condition
SEGAs presenting in an acute manner, such as with
symptomatic hydrocephalus, or with an acute intratumoral
hemorrhage may pose a life-threatening condition and
should be addressed surgically (Fig 1). Despite the acute
presentation, which often is associated with large tumors,
total gross resection can many times be safely achieved, but
care should be taken to minimize injury to neighboring
brain structures.
In sharp contrast to this scenario are those patients who
harbor asymptomatic tumors. These tumors may be diag-
nosed during screening magnetic resonance imaging scan-
ningandoftenarenot associatedwithhydrocephalusorother
mass effect. These tumors can be often followed with close
clinical and imaging follow-up. It is important to educate the
patient and family regarding potential presenting symptoms.
Most SEGAs, even in the presence of ventricular dilatation, do
not present acutely because of the insidious growth of the
lesion and gradual development of hydrocephalus.
The indication for treatment includes new onset of
symptoms or radiological evidence of tumor growth. These
patients may be treated surgically or medically in accor-
dance with other factors, as stated previously (Fig 2). Other
important factors that must be considered in decision-
making include both the age and the cognitive status of
the patient. Many TSC patients are signiﬁcantly
FIGURE 2.
This 6-year-old girl had a growing but asymptomatic tumor. (A) Her screening magnetic resonance imaging at age 2 revealed a, subependymal giant cell
astrocytoma with mild enlargement of the right lateral ventricle. (B) By age 6 years, the lesion had enlarged markedly. This is an example for which there is
no clear advantage for either treatment but advantages for each treatment (surgical or medical).
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convey early or subtle symptoms.
Anatomical consideration
SEGAs invasive to neighboring structures such as fornix
(especially the dominant one), hypothalamus, basal ganglia,
or genu of internal capsule, have a higher associated surgical
morbidity.32 Similarly, large-sized tumors are associatedwith
higher morbidity because of the need for more aggressive
tissue retraction and higher bleeding risks. Recurrent tumors
may suggest a more invasive nature of the tumor.27 These
conditions favor mTORi (Fig 3). Medical treatment is favored
as well in the case of multiple tumors, which are often bilat-
eral, and lesion(s) forwhichgross total resection isunlikely, as
residual tumor invariably will regrow (Figs 3,4).
Surgical experience
Not all neurosurgeons have extensive experience with
intraventricular tumors in general or SEGAs in particular.FIGURE 3.
A 26-year-old man with multiple intracranial subependymal giant cell astrocy
tumor. The multiple and anatomically unfavorable lesions justify mTOR inhibitmTORi as a single treatment, or as neoadjuvant (before
resection) treatment, may shrink the tumor and increase
surgical safety or obviate the need for surgery at all.
TSC-related comorbidities
Contraindication to surgery posed by cardiac, renal, or
pulmonary function would balance for mTORi, too.33
Despite their benign nature, cardiac rhabdomyomas may
cause arrhythmias and cardiac dysfunction, especially dur-
ing infancy. Renal and pulmonary dysfunctions are rare but
may pose a high surgical-anesthesiological risk, especially
in adults. In addition, mTORi may offer beneﬁts that
can never be expected from a neurosurgical procedure
in this population, such as reduction in angiomyolipoma
volume, improvement in facial angioﬁbromas, and
improvement in pulmonary function when intercurrent
lymphangioleiomyomatosis is present.34-36 Recent studies
have suggested a beneﬁcial effect on epilepsy as well.26,37-39
Additionally, early treatment with mTORi may alter the
natural disease course and prevent the development of TSC-tomas following bilateral shunts and partial resection of the left posterior
or treatment.
FIGURE 4.
This 9-year-old girl underwent subtotal resection of a right ventricular
subependymal giant cell astrocytoma 4 years earlier. She was lost to
follow-up until she presented with visual decline but no headaches. On
examination, she had optic atrophy and was nearly blind. Brain magnetic
resonance imaging showed a third ventricular tumor and a right temporal
horn tumor. This is an example of a patient for whom a shunt can be placed
followed by mTOR inhibitors.
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options in patients with other TSC-related comorbidities
that may beneﬁt from mTORi, this should be favored over
surgery.
Patient/parental preference
Nowadays many growing SEGAs are identiﬁed pre-
symptomatically and may be treated either surgically or
medically. It is important to present both treatment op-
tions to the family in a balanced way, taking into account
not only the SEGA, but the speciﬁc individual with the
variance of TSC associated comorbidities. Currently there is
no evidence for the superiority of one treatment over the
other, unless there are speciﬁc factors that favor one
treatment over another as discussed previously. SEGA pa-
tients should be discussed in a multidisciplinary team
including neurologists/oncologists and neurosurgeons to
thoroughly weigh pros and cons of the respective treat-
ment modality before ﬁnalizing an individualized treat-
ment recommendation.
The 2012 International TSC Clinical Consensus Conference was sponsored and
organized by the Tuberous Sclerosis Alliance. The conference was supported by
generous sponsors who donated funds to the Tuberous Sclerosis Alliance without
playing a role in the planning or having a presence at the conference or any inﬂuence
on the resulting recommendations: the Rothberg Institute for Childhood Diseases,
Novartis Pharmaceuticals, Sandra and Brian O’Brien, and Questcor Pharmaceuticals.
References
1. Borkowska J, Schwartz RA, Kotulska K, Jozwiak S. Tuberous sclerosis
complex: tumors and tumorigenesis. Int J Dermatol. 2011;50:13-20.2. Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet.
2008;372:657-668.
3. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex.
New Engl J Med. 2006;355:1345-1356.
4. Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis.
Ann NY Acad Sci. 1991;615:125-127.
5. Schwartz RA, Fernández G, Kotulska K, Józwiak S. Tuberous sclerosis
complex: advances in diagnosis, genetics, and management. J Am
Acad Dermatol. 2007;57:189-202.
6. Adriaensen ME, Schaefer-Prokop CM, Stijnen T, Duyndam DA,
Zonnenberg BA, Prokop M. Prevalence of subependymal giant cell
tumors in patients with tuberous sclerosis and a review of the
literature. Eur J Neurol. 2009;16:691-696.
7. Northrup H, Krueger D, for the 2012 International Tuberous Scle-
rosis Complex Consensus Group. Tuberous sclerosis complex diag-
nostic criteria update: Recommendations of the 2012 International
Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol.
2013;49:243-254.
8. Krueger D, Northrup H, for the 2012 International Tuberous Scle-
rosis Complex Consensus Group. Tuberous sclerosis complex sur-
veillance and management: Recommendations of the 2012
International Tuberous Sclerosis Complex Consensus Conference.
Pediatr Neurol. 2013;49:255-265.
9. Vaughn J, Hagiwara M, Katz J, et al. MRI characterization and lon-
gitudinal study of focal cerebellar lesions in a young tuberous
sclerosis cohort. AJNR Am J Neuroradiol. 2013;34:655-659.
10. Ertan G, Arulrajah S, Tekes A, Jordan L, Huisman TA. Cerebellar
abnormality in children and young adults with tuberous sclerosis
complex: MR and diffusion weighted imaging ﬁndings.
J Neuroradiol. 2010;37:231-238.
11. Katz JS, Milla SS, Wiggins GC, Devinsky O, Weiner HL, Roth J.
Intraventricular lesions in tuberous sclerosis complex: a possible
association with the caudate nucleus. J Neurosurg Pediatr. 2012;9:
406-413.
12. Bollo RJ, Berliner JL, Fischer I, et al. Extraventricular subependymal
giant cell tumor in a child with tuberous sclerosis complex.
J Neurosurg Pediatr. 2009;4:85-90.
13. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classiﬁcation
of tumours of the central nervous system. Acta Neuropathol. 2007;
114:97-109.
14. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex
consensus conference: Revised clinical diagnostic criteria. J Child
Neurol. 1998;13:624-628.
15. Matsumura H, Takimoto H, Shimada N, Hirata M, Ohnishi T,
Hayakawa T. Glioblastoma following radiotherapy in a patient with
tuberous sclerosis. Neurol Medico-chirurgica. 1998;38:287-291.
16. Sun P, Kohrman M, Liu J, Guo A, Rogerio J, Krueger D. Outcomes of
resecting subependymal giant cell astrocytoma (SEGA) among pa-
tients with SEGA-related tuberous sclerosis complex: a national
claims database analysis. Curr Med Res Opinion. 2012;28:657-663.
17. Jiang T, Jia G, Ma Z, Luo S, Zhang Y. The diagnosis and treatment of
subependymal giant cell astrocytoma combined with tuberous
sclerosis. Childs Nervous Syst. 2011;27:55-62.
18. Goh S, Butler W, Thiele EA. Subependymal giant cell tumors in tu-
berous sclerosis complex. Neurology. 2004;63:1457-1461.
19. Ekici MA, Kumandas S, Per H, et al. Surgical timing of the sub-
ependymal giant cell astrocytoma (SEGA) with the patients of tu-
berous sclerosis complex. Turkish Neurosurg. 2011;21:315-324.
20. de Ribaupierre S, Dorfmuller G, Bulteau C, et al. Subependymal giant-
cell astrocytomas in pediatric tuberous sclerosis disease: when
should we operate? Neurosurgery. 2007;60:83-89. discussion 89-90.
21. Cuccia V, Zuccaro G, Sosa F, Monges J, Lubienieky F, Taratuto AL.
Subependymal giant cell astrocytoma in children with tuberous
sclerosis. Childs Nervous Syst. 2003;19:232-243.
22. Amin S, Carter M, Edwards RJ, et al. The outcome of surgical man-
agement of subependymal giant cell astrocytoma in tuberous
sclerosis complex. Eur J Paediatr Neurol. 2013;17:36-44.
23. Krueger DA, Care MM, Holland K, et al. Everolimus for sub-
ependymal giant-cell astrocytomas in tuberous sclerosis. New Engl J
Med. 2010;363:1801-1811.
24. Krueger DA, Care MM, Agricola K, Tudor C, Mays M, Franz DN.
Everolimus long-term safety and efﬁcacy in subependymal giant
cell astrocytoma. Neurology. 2013;80:574-580.
25. Franz DN, Belousova E, Sparagana S, et al. Efﬁcacy and safety of
everolimus for subependymal giant cell astrocytomas associated
J. Roth et al. / Pediatric Neurology 49 (2013) 439e444444with tuberous sclerosis complex (EXIST-1): a multicentre, rand-
omised, placebo-controlled phase 3 trial. Lancet. 2013;381:
125-132.
26. Kotulska K, Chmielewski D, Borkowska J, et al. Long-term effect of
everolimus on epilepsy and growth in children under 3 years of
age treated for subependymal giant cell astrocytoma associated
with tuberous sclerosis complex. Eur J Paediatr Neurol. 2013;17:
479-485.
27. Franz DN, Agricola KD, Tudor CA, Krueger DA. Everolimus for tumor
recurrence after surgical resection for subependymal giant cell as-
trocytoma associated with tuberous sclerosis complex. J Child
Neurol. 2013;28:602-607.
28. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of
astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006;59:
490-498.
29. Campen CJ, Porter BE. Subependymal giant cell astrocytoma (SEGA)
treatment update. Curr Treatment Options Neurol. 2011;13:380-385.
30. Jozwiak S, Nabbout R, Curatolo P. Management of subependymal
giant cell astrocytoma (SEGA) associated with tuberous sclerosis
complex (TSC): clinical recommendations. Eur J Paediatr Neurol.
2013;17:348-352.
31. Agricola K, Tudor C, Krueger D, Neal D. Nursing implications for the
lifelong management of tuberous sclerosis complex. J Neurosci Nurs.
2013;45:223-239.
32. Isik U, Dincer A, Sav A, Ozek MM. Basal ganglia location of sub-
ependymal giant cell astrocytomas in two infants. Pediatr Neurol.
2010;42:157-159.33. Perek-Polnik M, Józwiak S, Jurkiewicz E, Perek D, Kotulska K.
Effective everolimus treatment of inoperable, life-threatening sub-
ependymal giant cell astrocytoma and intractable epilepsy in a
patient with tuberous sclerosis complex. Eur J Paediatr Neurol. 2012;
16:83-85.
34. McCormack FX, InoueY,Moss J, et al. Efﬁcacy and safety of sirolimus in
lymphangioleiomyomatosis. New Engl J Med. 2011;364:1595-1606.
35. Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for
angiomyolipoma associated with tuberous sclerosis complex or
sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre,
randomised, double-blind, placebo-controlled trial. Lancet. 2013;
381:817-824.
36. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyo-
lipoma in tuberous sclerosis complex or lymphangioleiomyoma-
tosis. New Engl J Med. 2008;358:140-151.
37. Cappellano AM, Senerchia AA, Adolfo F, et al. Successful everolimus
therapy for SEGA in pediatric patients with tuberous sclerosis
complex. Childs Nervous Syst; 2013 [e-pub ahead of print].
38. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus
treatment of refractory epilepsy in tuberous sclerosis complex. Ann
Neurol; 2013 [e-pub ahead of print].
39. Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN.
Everolimus in tuberous sclerosis patients with intractable epilepsy:
a treatment option? Eur J Paediatr Neurol; 2013 [e-pub ahead of
print].
40. Kotulska K, Borkowska J, Jozwiak S. Possible prevention of tuberous
sclerosis complex lesions. Pediatrics. 2013;132:e239-e242.
